Clinical trials: Hepatic Ascites
Ascites
Safety and Performance of the Automated Fluid Shunt in Patients With Ascites and Diuretic Resistance
To investigate the safety and performance of the Automated Fluid Shunt in patients with ascites and diuretic resistance. Study Size and Duration The primary study population will include 40 patients enrolled and implanted with…
- Trial name
- PIONEER (NCT01030185)
- Testing
- NovaShunt's Automated Fluid Shunt implantation
- Where
- 9 sites in Belgium, Bulgaria and 2 more
- Volunteers
- 40 people
- Sponsor
- NovaShunt AG
Ascites, Hepatic Cirrhosis
Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites
To observe the safety/efficacy of tolvaptan for treatment of patients with hepatic cirrhosis with ascites and exploring the dosage-effect relations of the drug.
- Trial name
- NCT01349335
- Testing
- Tolvaptan
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Otsuka Beijing Research Institute
Ascites, Hepatic Cirrhosis
Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
To evaluate the efficacy and safety of Tolvaptan 7.5mg and 15mg in treatment of patients with cirrhosis ascites who fail to response adequately to treatment with common diuretics.
- Trial name
- NCT01349348
- Testing
- Tolvaptan
- Where
- China
- Volunteers
- 535 people
- Sponsor
- Otsuka Beijing Research Institute
Hepatic Cirrhosis, Ascites
Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis
For hepatic cirrhosis subjects with ascites or lower extremities, to study Pharmacokinetics, pharmacology, and safety of the drug under fasting condition.
- Trial name
- NCT01359462
- Testing
- tolvaptan
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Otsuka Beijing Research Institute
Ascites, Liver Cirrhosis
Satavaptan Dose-Ranging Study in the Prevention of Ascites
The primary objective is to determine the optimal dose or range of doses of SR121463B for the reduction in recurrence of ascites, when used concomitantly with a standard dose regimen of spironolactone.
- Trial name
- SPA (NCT00501384)
- Testing
- satavaptan (SR121463B)
- Where
- 11 sites in Argentina, Australia and 9 more
- Volunteers
- 151 people
- Sponsor
- Sanofi
Ascites, Liver Cirrhosis
Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites
The primary objective is to determine the optimal dose or range of doses of SR121463B for the treatment of ascites and the correction of hyponatraemia when used concomitantly with a standard dose regimen of spironolactone.
- Trial name
- Hypo~CAT (NCT00501722)
- Testing
- satavaptan (SR121463B)
- Where
- 13 sites in United States, Argentina and 11 more
- Volunteers
- 110 people
- Sponsor
- Sanofi
Ascites, Liver Cirrhosis
Satavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic Ascites
The primary objective is to determine the optimal dose or range of doses of SR121463B for the treatment of ascites when used concomitantly with a standard dose regimen of spironolactone and furosemide.
- Trial name
- Normo~CAT (NCT00501566)
- Testing
- satavaptan (SR121463B)
- Where
- 12 sites in Argentina, Australia and 10 more
- Volunteers
- 148 people
- Sponsor
- Sanofi